Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS3-007
- Development stage
- Phase 2
- Lead developer
- Changchun GeneScience Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GS3-007 is a small molecule drug that acts as a Growth Hormone Releasing Hormone (GHRH) agonist. It is being developed by Changchun Genescience Pharmaceuticals for potential treatment of growth hormone deficiency and dyspepsia. The drug is administered orally and has been formulated as both an oral solution and dry suspension.
- Other names
- GS3-007a oral solutionGS-3-007a oral solutionGS 3-007a oral solutionGS3-007a dry suspensionGS-3-007a dry suspensionGS 3-007a dry suspensionGS3-007a for suspensionGS-3-007a for suspensionGS 3-007a for suspensionGS3-007a oral liquidGS-3-007a oral liquidGS 3-007a oral liquid
02
Targets
GHRHR (Growth hormone-releasing hormone receptor)
Beyond the preview
Go deeper on GS3-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS3-007.